Results 141 to 150 of about 6,358,445 (212)
Factors for Success and Failure of Allergen Immunotherapy (AIT) Trial Design in the Light of Evidence‐Based Medicine: Current Aspects 2026
Allergy, EarlyView.ABSTRACT
Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.Roy Gerth van Wijk, Vera Mahler, Melanie Albrecht, Danilo di Bona, Benjamin Hofner, Jasper Kappen, Susanne Kaul, Graham Roberts, Mohamed H. Shamji, Stefan Vieths, Oliver Pfaar +10 morewiley +1 more sourcePre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
Allergy, EarlyView.We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,Musa R. Khaitov, Maria G. Byazrova, Evgenii V. Smolnikov, Vladislav N. Turenko, Valeriy V. Smirnov, Igor P. Shilovskii, Nadezhda N. Shershakova, Ekaterina N. Medunitsyna, Olga G. Elisyutina, Mikhail V. Pashenkov, George B. Pasikhov, Vladimir V. Murugin, Veronika A. Parshina, Darya K. Bolyakina, Anastasia S. Primak, Mariya A. Lapyko, Inna V. Danilycheva, Rosalia V. Schubelko, Anastasia A. Tsyvkina, Nataliia V. Shartanova, Daria O. Timoshenko, Irina I. Isakova, Tatiana V. Latysheva, Andrey E. Shulzhenko, Elena A. Latysheva, Oksana M. Kurbacheva, Elena S. Fedenko, Oksana A. Markova, Ilya A. Korotkevich, Violetta V. Yan, Natalia A. Gavrilova, Mariia V. Tikhomirova, Ivan V. Shevchenko, Alena A. Agafonova, Gregory N. Poroshin, Dmitry A. Kudlay, Alexander V. Filatov, Evgeniya V. Nazarova, Daria S. Kruchko, Dmitriy V. Goryachev, Vadim A. Merkulov, Nataliya I. Ilina, Rudolf Valenta, Veronica I. Skvortsova +43 morewiley +1 more sourceAs‐Needed Versus Regular Medication Use in the Treatment of Allergic Rhinitis in the Pollen Season: A MASK‐air Study
Allergy, EarlyView.Using MASK‐air app data from 1042 users across 2690 weeks, this study compared the impact of regular versus as‐needed allergic rhinitis medication on symptom control and treatment satisfaction. Mixed‐effects linear regression models and sensitivity analyses revealed no significant differences between the two approaches, with results for oral ...Bernardo Sousa‐Pinto, Rafael José Vieira, Antonio Bognanni, Ludger Klimek, Ana Margarida Pereira, Rita Amaral, Anna Bedbrook, Patrizia Bonadonna, Luisa Brussino, Mark S. Dykewicz, Mattia Giovannini, Bilun Gemicioglu, Juan Carlos Ivancevich, Violeta Kvedariene, Manuel Marques‐Cruz, Matteo Martini, André Moreira, Marek Niedoszytko, Michal Ordak, Nikolaos G. Papadopoulos, Oliver Pfaar, Nhân Pham‐Thi, Orathai Jirapongsananuruk, Frederico S. Regateiro, Sanna K. Toppila‐Salmi, Joaquin Sastre, Luís Taborda‐Barata, Ilgım Vardaloğlu Koyuncu, Arunas Valiulis, Maria Teresa Ventura, Kangsadarn Tanjararak, Yi‐Kui Xiang, Mohamed H. Shamji, Maria José Torres, Holger J. Schünemann, Danilo di Bona, João A. Fonseca, Torsten Zuberbier, Jean Bousquet +38 morewiley +1 more sourceIgE‐Binding Bacterial Components Not Yet Documented in the Allergen Databases and Their Allergenic Mechanisms: An EAACI Position Paper
Allergy, EarlyView.ABSTRACT
Among bacteria that are associated with the development and/or exacerbation of allergic/atopic diseases, several have been described to produce IgE‐binding components. However, only one bacterial protein, Bac s 1, is currently listed in the official database of the World Health Organization/International Union of Immunological Societies (WHO ...Uta Jappe, Marua Abu Risha, Ioana Agache, Claus Bachert, Barbara Bröker, Riccardo Castagnoli, Gabriele Gadermaier, Richard E. Goodman, Amir Guemari, Christiane Hilger, Alain Jacquet, Sabine Kespohl, Ludger Klimek, Annette Kuehn, Jonas Lidholm, Vera Mahler, Markus Ollert, Thomas A. Platts‐Mills, Monika Raulf, Peter Schmid‐Grendelmeier, Frieder Schmiedeke, Marianne van Hage, Joana Vitte, Josefina Zakzuk, Anna Pomés +24 morewiley +1 more sourceUnderstanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases
Allergy, EarlyView.ABSTRACT
Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...Rodrigo Jiménez‐Saiz, Salvador Iborra, Carlos Blanco, Ruperto González‐Pérez, Emilio Nuñez‐Borque, Can Zeyneloglu, Huseyn Babayev, Ozlem Göksel, Tuncay Göksel, Musa Khaitov, Dmitry Kudlay, Yadong Gao, Mustafa Sevim, Marie‐Charlotte Brüggen, Oral Alpan, Ming Wang, Luo Zhang, María J. Torres, Mohamed Shamji, Mübeccel Akdis, Kari C. Nadeau, Ismail Ogulur, Cezmi A. Akdis +22 morewiley +1 more sourceThe Origins of Allergy: An Outside‐In, Bioenergetic Hypothesis
Allergy, EarlyView.ABSTRACT
Allergic disease has risen too rapidly for inherited susceptibility to explain it, and the risk variants so far reported lie in the epithelial barrier and in type‐2 immunity. We propose a five‐layer model in which epithelial barrier and bioenergetic dysfunction may precede and promote type‐2 immune deviation rather than arise solely as its ...Peter K. Smith, Nicholas P. West, Stanley Du Preez, Hugh A. Sampson, Peter W. Hellings, David Price, Liam O'Mahony, Carina Venter, Cezmi A. Akdis, Gil Yosipovitch +9 morewiley +1 more sourceTreatment of congestion in upper respiratory diseases
International Journal of General Medicine, 2010 Eli O Meltzer1, Fernan Caballero2, Leonard M Fromer3, John H Krouse4, Glenis Scadding51Allergy and Asthma Medical Group and Research Center, San Diego, CA and Department of Pediatrics, University of California, San Diego, USA; 2Allergy and Clinical ...Eli O Meltzer, Fernan Caballero, Leonard M Fromer, et al +3 moredoaj European Guidelines on Eosinophilic Esophagitis: Evidence‐Based Statements and Recommendations for Diagnosis and Management in Children and Adults. Part 1: Diagnosis, Epidemiology and Natural History
Allergy, EarlyView.The European evidence‐based guidelines on eosinophilic esophagitis (Part 1). This infographic summarizes the methodological framework and core clinical outputs of the updated consensus developed by multidisciplinary experts from EUREOS, EAACI, ESPGHAN, and ESP.Alfredo J. Lucendo, Javier Molina‐Infante, Ángel Arias, Ulrike von Arnim, Henrik Bergquist, Luc Biedermann, Albert J. Bredenoord, Marie Carlson, Javier Chahuan, Jorge Amil Dias, Thomas Eiwegger, Sara Feo‐Ortega, Sandra L. Garcia‐Dionisio, Matteo Ghisa, Jesús González‐Cervera, Thomas Greuter, Danila Guagnozzi, Carolina Gutiérrez‐Junquera, Lucía Gutiérrez‐Ramírez, Cord Langner, Helen Larsson, Anne Lund Krarup, Salvatore Oliva, Alexandra Papadopoulou, Francesca Racca, Cecilio Santander, Edoardo Vincenzo Savarino, Christoph Schlag, Alain M. Schoepfer, Martin A. Storr, Antonio Tejera‐Muñoz, Noam Zevit, Stephen E. Attwood, Alex Straumann +33 morewiley +1 more sourceEnvironmental Changes and Their Effect on the Airway Microbiome: Implications for Airway Diseases
Allergy, EarlyView.ABSTRACT
Obstructive airway diseases, including asthma and chronic obstructive pulmonary disease (COPD), represent the two major chronic airway inflammatory diseases. In both conditions, the airways are exposed to a variety of microbial and environmental stimuli.Georgios Rentzos, Evangelia Fouka, Nikolaos Lazarinis, Theo Gülen, Patricia Ramos‐Ramirez, Lauren Flynn, Stelios Loukides, Paraskevi Xepapadaki, Nikolaos G. Papadopoulos, Anders Lindén, Apostolos Bossios +10 morewiley +1 more sourceAn Extended Transcriptomic Landscape of Human Skin Mast Cells: Unveiling Lineage‐Specific Noncoding RNA Dynamics in FcεRI Activation
Allergy, EarlyView.FcεRI cross‐linking triggers widespread transcriptional reprogramming in human skin mast cells (> 5000 genes, > 6400 promoters, and 48 novel mast cell‐enriched lncRNAs). Breast skin and foreskin mast cells share core transcriptional programs but differ selectively in tryptase isoenzymes and IL‐8/IL‐1RA release.Gürkan Bal, Kristin Franke, Stefan Frischbutter, Shiva Raj Tripathi, Kayoko Yasuzawa, Jordan A. Ramilowski, Michihira Tagami, Takeya Kasukawa, Michiel de Hoon, Jay W. Shin, Piero Carninci, Torsten Zuberbier, Magda Babina +12 morewiley +1 more source
